+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID07365241

Evaluating ABBV-706 Compared to Standard Treatments in Adults With Relapsed or Refractory Small Cell Lung Cancer

Led by AbbVie · Updated on 2026-09-23

531

Participants Needed

72

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety, tolerability, and changes in disease activity of an investigational drug called ABBV-706 compared to standard treatments for relapsed or refractory small cell lung cancer SCLC, a fast-growing cancer that often spreads early to other parts of the body. This Phase 3 trial involves about 531 adult participants worldwide and aims to assess how ABBV-706 works against current standard care options including topotecan, lurbinectedin, or amrubicin. Participants with SCLC will be randomly assigned to receive either ABBV-706 or one of the standard care treatments. ABBV-706 and the comparator drugs are given through intravenous infusion, with topotecan also available orally. The entire study is expected to last approximately 53 months, during which participants will receive their assigned treatment as part of this extended timeframe. During the study, participants will attend regular visits at a hospital or clinic for medical assessments, which include blood tests, scans, and questionnaires to monitor disease progression and treatment effects. Researchers will measure outcomes such as overall response rate, overall survival, progression-free survival, and quality of life changes. Safety and adverse events will be tracked throughout the study duration of up to 53 months.

CONDITIONS

Brief Title

A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer

Research Team

A

ABBVIE CALL CENTER

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here